We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other biotech stocks that dominate Monday’s top gainers.

The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major indices finishing in the green following President Donald Trump’s temporary tax reprieve on technology companies.

The S&P 500 recorded the highest gain, up 0.79 percent, while the Dow Jones came second at 0.78 percent. The tech-heavy Nasdaq was also up by 0.64 percent.

Benchmark indices aside, 10 companies dominated by biotechnology firms mirrored the broader market optimism, recording modest gains during the session.

In this article, let us explore Monday’s top 10 gainers and the reasons behind their gains.

To come up with the list, we only considered the stocks with $2 billion market capitalization and $5 million trading volume.

Certara Inc. (NASDAQ:CERT)

Shares of Certara Inc. surged by 11.54 percent on Monday to finish at $14.40 apiece as investors cheered the company’s launch of its Non-Animal Navigator (NAN) solution, supporting the Food and Drug Administration’s (FDA) decision last week to reduce animal testing in preclinical safety studies.

According to CERT, the NAN is a flexible solution that offers strategic regulatory advice, an integrated preclinical development plan, and an optimized AI-enabled modeling toolkit, all of which would ensure that clients’ development programs “are compliant, agile, and future-ready.”

“The FDA announcement and roadmap pave the way for more model-informed drug development approaches that are predictive, efficient, and ethical,” said CERT Chief Executive Officer William F. Feehery. ”It is part of a growing industry adoption trend to use scientifically robust new approach methodologies (NAMs) like AI-enabled biosimulation to improve strategic decision-making and success rates at every phase of drug development.”

CERT is a company engaged in biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Overall, CERT ranks 4th on our list of biotech stocks that dominate Monday’s top gainers. While we acknowledge the potential of CERT as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CERT but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.